These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 2302378)

  • 41. Identification of susceptibility to malignant hyperpyrexia in swine.
    Okumura F; Crocker BD; Denborough MA
    Br J Anaesth; 1979 Mar; 51(3):171-6. PubMed ID: 435338
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A comparison of the caffeine halothane muscle contracture test with the molecular genetic diagnosis of malignant hyperthermia.
    MacKenzie AE; Allen G; Lahey D; Crossan ML; Nolan K; Mettler G; Worton RG; MacLennan DH; Korneluk R
    Anesthesiology; 1991 Jul; 75(1):4-8. PubMed ID: 2064058
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Porcine malignant hyperthermia: effects of temperature and extracellular calcium concentration on halothane-induced contracture of susceptible skeletal muscle.
    Nelson TE; Bedell DM; Jones EW
    Anesthesiology; 1975 Mar; 42(3):301-6. PubMed ID: 1115384
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative analysis of in vitro contracture tests with ryanodine and a combination of ryanodine with either halothane or caffeine: a comparative investigation in malignant hyperthermia.
    Bendahan D; Guis S; Monnier N; Kozak-Ribbens G; Lunardi J; Ghattas B; Mattei JP; Cozzone PJ
    Acta Anaesthesiol Scand; 2004 Sep; 48(8):1019-27. PubMed ID: 15315621
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Failure of the platelet-halothane nucleotide depletion test as a diagnostic or screening test for malignant hyperthermia.
    Britt BA; Scott EA
    Anesth Analg; 1986 Feb; 65(2):171-5. PubMed ID: 3942305
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reproducibility of in vitro contracture test results in patients tested for malignant hyperthermia susceptibility.
    Islander G; Ording H; Bendixen D; Ranklev Twetman E
    Acta Anaesthesiol Scand; 2002 Oct; 46(9):1144-9. PubMed ID: 12366511
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Contracture test with ionophore A 23187 for the diagnosis of malignant hyperthermia].
    Moeller R; Kozak-Reiss G; Gascard JP; Laxenaire MC
    Ann Fr Anesth Reanim; 1986; 5(2):177-81. PubMed ID: 3089080
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Is there a link between exertional heat stroke and susceptibility to malignant hyperthermia?
    Sagui E; Montigon C; Abriat A; Jouvion A; Duron-Martinaud S; Canini F; Zagnoli F; Bendahan D; Figarella-Branger D; Brégigeon M; Brosset C
    PLoS One; 2015; 10(8):e0135496. PubMed ID: 26258863
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sevoflurane as a potential replacement for halothane in diagnostic testing for malignant hyperthermia susceptibility: results of a preliminary study.
    Metterlein T; Hartung E; Schuster F; Roewer N; Anetseder M
    Minerva Anestesiol; 2011 Aug; 77(8):768-73. PubMed ID: 21730923
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prediction of malignant hyperthermia susceptibility in low-risk subjects. An epidemiologic investigation of caffeine halothane contracture responses. The North American Malignant Hyperthermia Registry.
    Larach MG; Landis JR; Bunn JS; Diaz M
    Anesthesiology; 1992 Jan; 76(1):16-27. PubMed ID: 1729931
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Malignant hyperthermia testing in patients with persistently increased serum creatine kinase levels.
    Weglinski MR; Wedel DJ; Engel AG
    Anesth Analg; 1997 May; 84(5):1038-41. PubMed ID: 9141928
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Diagnosis of susceptibility to malignant hyperthermia in children].
    Krivosic-Horber R; Adnet P; Krivosic I; Reyford H
    Arch Fr Pediatr; 1990; 47(6):421-4. PubMed ID: 2403268
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety of general anesthesia in patients previously tested negative for malignant hyperthermia susceptibility.
    Allen GC; Rosenberg H; Fletcher JE
    Anesthesiology; 1990 Apr; 72(4):619-22. PubMed ID: 2321777
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Porcine malignant hyperthermia: false negatives in the halothane test.
    Gallant EM; Rempel WE
    Am J Vet Res; 1987 Mar; 48(3):488-91. PubMed ID: 3565905
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro contracture testing for determination of susceptibility to malignant hyperthermia: a methodologic update.
    Iaizzo PA; Wedel DJ; Gallagher WJ
    Mayo Clin Proc; 1991 Oct; 66(10):998-1004. PubMed ID: 1833602
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The in vitro determination of susceptibility to malignant hyperthermia.
    Iaizzo PA; Lehmann-Horn F
    Muscle Nerve; 1989 Mar; 12(3):184-90. PubMed ID: 2725548
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Procaine in malignant hyperpyrexia.
    Moulds RF; Denborough MA
    Br Med J; 1972 Dec; 4(5839):526-8. PubMed ID: 4642792
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Viability criterion of muscle bundles used in the in vitro contracture test in patients with neuromuscular diseases.
    Adnet PJ; Krivosic-Horber RM; Krivosic I; Haudecoeur G; Reyford HG; Adamantidis MM; Medahoui H
    Br J Anaesth; 1994 Jan; 72(1):93-7. PubMed ID: 8110560
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacological in-vitro studies in malignant hyperthermia in childhood.
    Mortier W; Biesel C
    Brain Dev; 1982; 4(5):347-52. PubMed ID: 7137513
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In-vitro contracture testing for susceptibility to malignant hyperthermia: can halothane be replaced?
    Metterlein T; Schuster F; Kranke P; Roewer N; Anetseder M
    Eur J Anaesthesiol; 2011 Apr; 28(4):251-5. PubMed ID: 20827211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.